Switch theme
Sign up to access all valuation multiples
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is engaged in the development of a specific oligomer-directed vaccine (ALZ-101), and ALZ-201 which is a monoclonal antibody that is specific for the toxic AB oligomers. The products of the company are in the clinical and preclinical stages of development as a therapeutic vaccine for the treatment of Alzheimer’s.
2011
5
LTM Revenue $1.6M
LTM EBITDA -$1.0M
$16.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alzinova has a last 12-month revenue (LTM) of $1.6M and a last 12-month EBITDA of -$1.0M.
In the most recent fiscal year, Alzinova achieved revenue of n/a and an EBITDA of -$2.1M.
Alzinova expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alzinova valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $1.6M | XXX | $1.7M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$1.0M | XXX | -$2.1M | XXX | XXX | XXX |
| EBITDA Margin | -65% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$1.1M | XXX | -$2.1M | XXX | XXX | XXX |
| EBIT Margin | -66% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$1.1M | XXX | -$2.1M | XXX | XXX | XXX |
| Net Margin | -66% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alzinova's stock price is SEK 2 (or $0).
Alzinova has current market cap of SEK 177M (or $18.3M), and EV of SEK 162M (or $16.8M).
See Alzinova trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16.8M | $18.3M | XXX | XXX | XXX | XXX | $-0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alzinova has market cap of $18.3M and EV of $16.8M.
Alzinova's trades at 601.6x EV/Revenue multiple, and -8.0x EV/EBITDA.
Equity research analysts estimate Alzinova's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alzinova has a P/E ratio of -17.3x.
See valuation multiples for Alzinova and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $18.3M | XXX | $18.3M | XXX | XXX | XXX |
| EV (current) | $16.8M | XXX | $16.8M | XXX | XXX | XXX |
| EV/Revenue | 10.5x | XXX | 601.6x | XXX | XXX | XXX |
| EV/EBITDA | -16.1x | XXX | -8.0x | XXX | XXX | XXX |
| EV/EBIT | -15.9x | XXX | -8.0x | XXX | XXX | XXX |
| EV/Gross Profit | 10.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -17.3x | XXX | -8.6x | XXX | XXX | XXX |
| EV/FCF | -5.6x | XXX | -4.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlzinova's last 12 month revenue growth is 42%
Alzinova's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.8M for the same period.
Alzinova's rule of 40 is -6026% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alzinova's rule of X is 39% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alzinova and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -65% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 105% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -6026% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alzinova acquired XXX companies to date.
Last acquisition by Alzinova was XXXXXXXX, XXXXX XXXXX XXXXXX . Alzinova acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alzinova founded? | Alzinova was founded in 2011. |
| Where is Alzinova headquartered? | Alzinova is headquartered in Sweden. |
| How many employees does Alzinova have? | As of today, Alzinova has 5 employees. |
| Is Alzinova publicy listed? | Yes, Alzinova is a public company listed on STO. |
| What is the stock symbol of Alzinova? | Alzinova trades under ALZ ticker. |
| When did Alzinova go public? | Alzinova went public in 2015. |
| Who are competitors of Alzinova? | Similar companies to Alzinova include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Alzinova? | Alzinova's current market cap is $18.3M |
| What is the current revenue of Alzinova? | Alzinova's last 12 months revenue is $1.6M. |
| What is the current revenue growth of Alzinova? | Alzinova revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of Alzinova? | Current revenue multiple of Alzinova is 10.5x. |
| Is Alzinova profitable? | Yes, Alzinova is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alzinova? | Alzinova's last 12 months EBITDA is -$1.0M. |
| What is Alzinova's EBITDA margin? | Alzinova's last 12 months EBITDA margin is -65%. |
| What is the current EV/EBITDA multiple of Alzinova? | Current EBITDA multiple of Alzinova is -16.1x. |
| What is the current FCF of Alzinova? | Alzinova's last 12 months FCF is -$3.0M. |
| What is Alzinova's FCF margin? | Alzinova's last 12 months FCF margin is -188%. |
| What is the current EV/FCF multiple of Alzinova? | Current FCF multiple of Alzinova is -5.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
